X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare GSK Pharma with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GSK PHARMA vs ASTRAZENECA PHARMA - Comparison Results

GSK PHARMA    Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GSK PHARMA ASTRAZENECA PHARMA GSK PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 53.5 118.3 45.2% View Chart
P/BV x 10.6 22.9 46.3% View Chart
Dividend Yield % 2.7 0.0 -  

Financials

 GSK PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    GSK PHARMA
Mar-18
ASTRAZENECA PHARMA
Mar-18
GSK PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs2,7601,278 216.0%   
Low Rs2,040883 231.1%   
Sales per share (Unadj.) Rs339.0228.4 148.4%  
Earnings per share (Unadj.) Rs41.410.4 399.6%  
Cash flow per share (Unadj.) Rs45.916.3 282.3%  
Dividends per share (Unadj.) Rs35.000-  
Dividend yield (eoy) %1.50-  
Book value per share (Unadj.) Rs242.998.8 245.9%  
Shares outstanding (eoy) m84.7025.00 338.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x7.14.7 149.7%   
Avg P/E ratio x57.9104.2 55.6%  
P/CF ratio (eoy) x52.366.4 78.7%  
Price / Book Value ratio x9.910.9 90.3%  
Dividend payout %84.50-   
Avg Mkt Cap Rs m203,28027,008 752.7%   
No. of employees `000NA1.4 0.0%   
Total wages/salary Rs m5,2341,535 340.9%   
Avg. sales/employee Rs ThNM4,210.9-  
Avg. wages/employee Rs ThNM1,132.2-  
Avg. net profit/employee Rs ThNM191.1-  
INCOME DATA
Net Sales Rs m28,7155,710 502.9%  
Other income Rs m545123 445.2%   
Total revenues Rs m29,2605,833 501.7%   
Gross profit Rs m5,059463 1,092.8%  
Depreciation Rs m380147 257.8%   
Interest Rs m20-   
Profit before tax Rs m5,222438 1,192.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m1780-   
Tax Rs m1,892179 1,057.6%   
Profit after tax Rs m3,508259 1,353.9%  
Gross profit margin %17.68.1 217.3%  
Effective tax rate %36.240.8 88.7%   
Net profit margin %12.24.5 269.2%  
BALANCE SHEET DATA
Current assets Rs m21,8153,209 679.8%   
Current liabilities Rs m15,9992,070 773.1%   
Net working cap to sales %20.320.0 101.5%  
Current ratio x1.41.6 87.9%  
Inventory Days Days6472 87.9%  
Debtors Days Days1935 53.5%  
Net fixed assets Rs m12,475790 1,578.5%   
Share capital Rs m84750 1,694.0%   
"Free" reserves Rs m19,7262,419 815.4%   
Net worth Rs m20,5732,469 833.2%   
Long term debt Rs m60-   
Total assets Rs m39,4754,605 857.1%  
Interest coverage x2,612.0NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.71.2 58.7%   
Return on assets %8.95.6 158.0%  
Return on equity %17.110.5 162.5%  
Return on capital %26.217.7 148.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m564300 188.3%   
Fx outflow Rs m7,4292,015 368.7%   
Net fx Rs m-6,865-1,715 400.2%   
CASH FLOW
From Operations Rs m4,72888 5,378.8%  
From Investments Rs m-1,042-94 1,113.1%  
From Financial Activity Rs m-3,066NA-  
Net Cashflow Rs m620-6 -10,871.9%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 50.7 75.0 67.6%  
Indian inst/Mut Fund % 10.2 0.3 3,400.0%  
FIIs % 23.8 15.7 151.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 15.4 9.1 169.2%  
Shareholders   102,036 12,856 793.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GSK PHARMA With:   IPCA LABS  SANOFI INDIA  PANACEA BIOTECH  MERCK  NOVARTIS  

Compare GSK PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 324 Points Lower; Metal and Telecom Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

ASTRAZENECA PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 381.0% (Quarterly Result Update)

Feb 12, 2019 | Updated on Feb 12, 2019

For the quarter ended December 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 291 m (up 381.0% YoY). Sales on the other hand came in at Rs 2 bn (up 67.4% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 66.7% (Quarterly Result Update)

Nov 27, 2018 | Updated on Nov 27, 2018

For the quarter ended September 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 91 m (down 66.7% YoY). Sales on the other hand came in at Rs 2 bn (down 1.8% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

More Views on News

Most Popular

This is Why the Stock of Jubilant FoodWorks Went Up 1,160%(The 5 Minute Wrapup)

Apr 12, 2019

This critical business strategy has enabled companies to scale their operations faster.

Pocketing Massive Gains with HDFC And HDFC Bank(Profit Hunter)

Apr 12, 2019

Here's how one could have generated gains of Rs 59,250 in 10 days by trading HDFC and HDFC Bank with a capital of Rs 4 lakh.

My Master Series on How to Trade Election 2019(Profit Hunter)

Apr 16, 2019

For 30 years he has watched how elections impact the markets, and practiced how to profit from it. Now he is here...telling you everything. Read on...

Election Series: Follow the World's Biggest Traders To See Where the Money Flows(The 5 Minute Wrapup)

Apr 17, 2019

20% of all the traders bring in 80% of the money. Watch these 20% and you get a working idea of which way the wind is blowing.

A Letter to You from India's No. 1 Trader(The 5 Minute Wrapup)

Apr 15, 2019

It's our great pleasure to introduce Vijay Bhambwani to our readers - we consider Vijay to be India's best trader. Read on to find out why...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GSK PHARMA SHARE PRICE


Apr 25, 2019 (Close)

TRACK GSK PHARMA

  • Track your investment in GSK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

GSK PHARMA - BIOCON COMPARISON

COMPARE GSK PHARMA WITH

MARKET STATS